Boehringer Ingelheim: latest news - GoINPHARMA
Wednesday, 19 September 2018 - 12:13

Boehringer Ingelheim

Boehringer Ingelheim invests €200m in new site creating 100 jobs

Germany-based Boehringer Ingelheim has confirmed it is among the companies investing the most in research and production capacity. The company has announced this week a €200m investment to build a new veterinary products manufacturing site in the French region Rhône-Alpes….

Biosimilar to Humira developed by Boehringer Ingelheim approved in Europe

The European Medicines Agency (EMA) has approved Boehringer Ingelheim’s Cyltezo, biosimilar to AbbVie’s blockbuster Humira. The Agency has recently approved the biosimilar to Humira developed by Amgen as well, which will be marketed as of October 2018 as Amgevita. The…

NASH: agreement between Boehringer Ingelheim and Dicerna Pharmaceuticals

Boehringer Ingelheim and Dicerna Pharmaceuticals, a company focusing on developing RNAi (RNA interference) therapies, have announced they have signed a research and license agreement in order to develop therapies addressing chronic liver diseases through Dicerna’s GalXC platform. The partnership will…

Boehringer Ingelheim obtains FDA approval for biosimilar to Humira

Boehringer Ingelheim has obtained approval by the FDA for Cyltezo, the biosimilar to AbbVie’s immunosuppressant Humira. Cyltezo is the first biosimilar by the Germany-based group to be approved and is fairly significant as it provides an alternative to the best-selling…

Boehringer Ingelheim/Pharmaxis start Phase IIa trial in NASH

Boehringer Ingelheim and Pharmaxis yesterday announced they have started a Phase IIa trial assessing BI 1467335 in NASH. The drug is an oral inhibitor which works by blocking leukocyte adhesion and tissue infiltration in inflammatory processes underlying the disease. NAFLD…

Boehringer Ingelheim growing again: amazing second quarter results

After years of moderate growth, the private pharmaceutical group Boehringer Ingelheim is now resuming a strong development. The group’s management announced today its H1 2017 results, which exceeded every prediction. The Germany-based group’s Sales were up 27%, to €9.2bn. Boehringer…

Hurbertus von Baumbach talks about Boehringer Ingelheim’s strategy

Hubertus von Baumbach, the great-grandson of Boehringer Ingelheim’s founder, gave an interview to German economic and financial daily Handelsblatt, in which he announced the group’s strategy. Boehringer will keep seeking cooperation agreements with external partners through its new “Research Beyond…

Biosimilar to Humira draws closer to commercialization

Boehringer Ingelheim announced today that adalimumab (BI 695501), biosimilar to AbbVie’s Humira, has been accepted to undergo the approval process by both EMA and FDA. Adalimumab is a monoclonal antibody that blocks mediators of inflammation TNF-α. The product is approved…

Restructuring in sight for Boehringer Ingelheim (900 units)

Germany-based pharma group Boehringer Ingelheim will reduce its workforce by 900 units in the next years. The sites most radically affected by the restructuring will be Ingelheim’s HQ and, to a lesser extent, Biberach and Dortmund. The company is currently…